Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 16/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 16/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 16/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 16/20 | 0.53 |
| ▸ | PRKAG3 | Q9UGI9 | 16/20 | 0.53 |
| ▸ | PRKAG2 | Q9UGJ0 | 16/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 16/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490344 | 0.88 | CYP1A2 (0.57) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL6490982 | 0.85 | GSK3B (0.55) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL6477985 | 0.85 | GSK3B (0.56) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL3361082 | 0.84 | JAK2 (0.57) | GSK3BPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL6479588 | 0.84 | GSK3B (0.61) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL6488817 | 0.83 | PDPK1 (0.58) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL27623401 | 0.82 | PRKAB2 (0.57) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL13525178 | 0.79 | JAK2 (0.52) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL6487188 | 0.77 | GSK3B (0.57) | CYP1A2GSK3BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12907187 | 0.76 | JAK2 (0.72) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | CYP1A2 49/4885GSK3B 2342/4885PRKAB2 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.